EUCTR2014-002279-27-LV进行中（未招募）1 期
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Three-Arm, Multi-Site Study to Evaluate the Clinical Equivalence of Diclofenac Sodium Topical Gel 1% (Hi-Tech Pharmacal Co., Inc.) with Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%(Novartis) in Patients with Osteoarthritis of the Knee.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Ambulatory male and non-pregnant females 35 years and older diagnosed with osteoarthritis according to the American College of Rheumatology Criteria (ACR) (Appendix 2) in target knee. Target knee is the one with higher level of pain.
- •ACR Criteria includes: Knee Pain and at least 3 of the following:
- •1)age = 50
- •2)stiffness lasting < 30 mins
- •3)bony tenderness
- •4)crepitus
- •5)bony enlargement
- •6)no palpable warmth
- •2.Symptom onset of > 6 Months prior to Screening for the target knee.
- •3.If female and of child-bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., IUD, oral, transdermal, injected, implanted hormonal contraceptives or condom + spermicide).
- •4.Periarticular knee pain due to osteoarthritis (not bursitis, tendonitis etc) that required the use of oral or topical treatments (e.g. NSAIDS or acetaminophen).
- •5.Radiograph of the target knee within the previous year with a Grade 1, 2 or 3 disease based upon the Kellgren-Lawrence disease severity scale (Appendix 3).
- •6.After a minimum of 7-day wash out of all pain medication has baseline pain on movement score of = 50mm on a 0-100-mm Visual Analogue Scale for the target knee.
- •7.After a minimum of 7 day wash out of all pain medication has baseline WOMAC pain sub scale of = 9 on a 5 question, 5 point (0 to 4) Likert scale for the target knee.
- •8.Willing and able to use only acetaminophen as rescue medication.
- •9.Willing and able to comply with the study requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 800
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Females who are pregnant, breast feeding, or planning a pregnancy.
- •2.Radiograph of the target knee within the previous year with a Grade 4 score on the Kellgren-Lawrence disease severity scale (Appendix 3).
- •3.History of osteoarthritis in the contralateral knee requiring medication within 12 months of screening.
- •4.After a minimum of 7-day wash out of all pain medication has baseline pain on movement score of = 20mm on a 0-100-mm Visual Analogue Scale for the contralateral knee immediately prior to randomization.
- •5.Known history of secondary osteoarthritis (e.g. congenital, traumatic, gouty arthritis) of the knee or rheumatoid arthritis.
- •6.Known history of other chronic inflammatory diseases, (e.g., colitis) or fibromyalgia during last 5 years. Patients whose disease was diagnosed at least 5 (five) years prior to screening visit and have had no known disease activity (i.e., no disease related complaints nor disease treatment prescribed) since then may enter into the study.
- •7.History of asthma, hypertension, myocardial infarction, thrombotic events, stroke, congestive heart failure, impaired renal function or liver disease. Patients who have had high blood pressure measured at least 2 (two) years prior to screening visit and have had no disease activity (i.e., no record of hypertension nor anti-hypertensive treatment prescribed) for at least 2 (two) years prior to screening visit may enter into the study.
- •8.History of coronary artery bypass graft within 6 months of screening.
- •9.Concomitant acetylsalicylic acid therapy other than a stable low dose used for cardiac prophylaxis (max 162 mg daily) taken for at least 3 months prior to enrollment and maintained throughout the duration of the study.
- •10.Use of warfarin or other anticoagulant therapy within 30 days of screening.
- •11.Use of ACE inhibitors, cyclosporine, diuretics, lithium or methotrexate, within 30 days of screening or during the study.
- •12.Known history of gastrointestinal bleeding or peptic ulcer disease.
- •13.Abnormal screening clinical laboratory evaluations which the Investigator deems clinically significant.
- •14.Known allergy to aspirin or NSAIDs.
- •15.Skin lesions or wounds in the affected area.
- •16.Significant (requiring surgery) injury or major knee surgery to either knee within six months prior to screening.
- •17.Transaminase levels that are more than two times the upper limit of the normal range at screening.
- •18.Any other acute or chronic illness that in the opinion of the investigator could compromise the integrity of study data or place the Patient at risk by participating in the study.
- •19.Concomitant use of corticosteroids (any formulation) or use within 30 days of study randomization.
- •20.Receipt of any drug as part of a research study within 30 days prior to screening.
- •21.Previous randomization into this study.
- •22. Known allergy (hypersensitivity) to acetaminophen.
研究者
相似试验
进行中（未招募）
不适用
Study of the safety and effectiveness of two doses of investigational study drug EVP-6124 in subjects with Alzheimer’s DiseaseEUCTR2013-002653-30-ITEnVivo Pharmaceuticals, Inc.790
进行中（未招募）
不适用
Efficacy and Safety of REGN727/SAR236553 Versus Placebo in Patients with Heterozygous Familial Hypercholesterolemia Not Adequately Controlled with Their Lipid-Modifying TherapyEUCTR2012-001222-95-NLRegeneron Pharmaceuticals Inc.250
已完成
3 期
Once-A-Day Pregabalin For Partial SeizuresCTRI/2011/08/001976Pfizer Limited264
进行中（未招募）
1 期
Research study to evaluate SEP-4199 (the study drug) for the Treatment of Depressive Episodes in patients with Bipolar I Disorder.EUCTR2018-000103-16-BGSUNOVION PHARMACEUTICALS INC.341
进行中（未招募）
1 期
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With AlirocumabMedDRA version: 19.0Level: PTClassification code 10051592Term: Acute coronary syndromeSystem Organ Class: 10007541 - Cardiac disordersAcute coronary syndromeEUCTR2011-005698-21-EEsanofi-aventis Recherche & Développement18,600